Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared With Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer

PLoS ONE - United States
doi 10.1371/journal.pone.0102777
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients

Korean Journal of Internal Medicine
Internal Medicine
2007English

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

OncoTargets and Therapy
OncologyPharmacology
2016English

Sequential Treatment of Tyrosine Kinase Inhibitors and Chemotherapy for EGFR-mutated Non-Small Cell Lung Cancer: A Meta-Analysis of Phase III Trials

OncoTargets and Therapy
OncologyPharmacology
2013English

ALK, ROS1 and EGFR Next-Generation Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer

Oncology in Clinical Practice
Oncology
2019English

Economic Evaluation of First Line Treatment for Advanced Non Small Cell Lung Cancer Using Tyrosine Kinase Inhibitors in Malaysia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

Oncologist
Cancer ResearchMedicineOncology
2015English

Non-Small Cell Lung Cancer-Small Cell Lung Cancer Transformation as Mechanism of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

2020English

P1.01-19 Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastases

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Influence of EGFR-activating Mutations on Sensitivity to Tyrosine Kinase Inhibitors in a KRAS Mutant Non-Small Cell Lung Cancer Cell Line

PLoS ONE
Multidisciplinary
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy